hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%) research hub

C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY

This study looks at the long-term safety and how well new gene therapies work for people with haemophilia A or B. Researchers want to see if these treatments prevent bleeding and if there are any side effects over time, like blood clots or liver problems. It's for adult males.